Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Icoat Medical AB operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are handled by 2 distinct examiners, which indicates that each pending matter is being reviewed by a different individual. This distribution suggests that the company's legal strategy is not reliant on a single examiner's interpretation of the claims.
The prosecution activity is situated within 2 distinct art units. BAKSHI, PANCHAM is the busiest examiner for the company, managing 1 busiest examiner pending office action. This action is part of the 2 pending office actions for the portfolio. Because the company is dealing with 2 distinct art units, the prosecution strategy must remain flexible to accommodate the varying requirements of different technical divisions. The data shows that the busiest examiner is only responsible for 1 pending matter, reflecting a balanced workload across the current filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17297112 | EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17297112 | EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES | BEHARRY, ZANNA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17297112 | EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES | BEHARRY, ZANNA MARIA | 1632 | §103 | Final Rejection | — | Pending | May 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIcoat Medical AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zanna Maria Beharry has the most, with 1 of Icoat Medical AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
